Immutep to Present Final Overall Survival Data From Phase IIb AIPAC as a Late Breaking Poster Presentation at SITC 2021

SYDNEY, Australia, Sept. 21, 2021 (GLOBE NEWSWIRE) — Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, is pleased to announce it will report final Overall Survival (OS) data from its Phase IIb AIPAC clinical trial evaluating lead product candidate eftilagimod alpha (“efti” or “IMP321”) in metastatic breast cancer at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2021. SITC 2021 is taking place in Washington, US and virtually from 10-14 November.

The final OS data will be presented by Immutep at SITC 2021 as a late breaker poster presentation. Interim OS data from the trial was presented in a spotlight presentation at the San Antonio Breast Cancer Symposium in December 2020.

Immutep will make the poster available on its website following publication at SITC 2021 and will host a webinar for investors after the conference.

About
the Society for Immunotherapy of Cancer (SITC)

SITC is the world’s leading member-driven organisation specifically dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy. The SITC Annual Meeting is the largest conference solely focused on cancer immunotherapy and brings together stakeholders across the cancer immunotherapy field to advance the science, discover breakthroughs and educate the world on cancer immunotherapy.

About AIPAC

AIPAC is a multi-centre Phase IIb clinical trial evaluating eftilagimod alpha (“efti” or “IMP321”) in combination with paclitaxel, a standard of care chemotherapy, as a chemo-immunotherapy combination. The trial is a randomised, double blinded, placebo-controlled clinical study with 227 evaluated HR+/HER2- metastatic breast cancer patients and is taking place across more than 30 clinical trial sites in Germany, UK, France, Hungary, Belgium, Poland, and the Netherlands. The combination therapy aims to boost the body’s immune response against tumour cells compared to chemotherapy plus placebo.

Immutep announced first overall survival (OS) data from approximately 60% of events at the San Antonio Breast Cancer Symposium 2020 in December 2020, reporting a promising and improving overall trend in OS with a median survival benefit of +2.7 months from efti plus chemotherapy (“efti group”), compared to chemotherapy plus placebo (“placebo group”). In addition, a statistically significant OS benefit was observed in the efti group in key pre-defined patient groups:

  • in patients under 65 years of age, a +7.1 month survival benefit was observed in the efti group which reported a median OS of 21.9 months vs. 14.8 months in the placebo group, reflecting nearly 50% longer survival; and
  • in patients with a low starting monocyte count, a +9.4 month survival benefit was observed in the efti group, with a median OS of 22.4 months vs. 12.9 months in the placebo group, nearly 75% longer.

About Immutep

Immutep is a globally active biotechnology company that is a leader in the development of LAG-3 related immunotherapeutic products for the treatment of cancer and autoimmune disease. Immutep is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximize value to shareholders. Immutep is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the United States.

Immutep’s current lead product candidate is eftilagimod alpha (“efti” or “IMP321”), a soluble LAG-3 fusion protein (LAG-3Ig), which is a first-in-class antigen presenting cell (APC) activator being explored in cancer and infectious disease. Immutep is also developing an agonist of LAG-3 (IMP761) for autoimmune disease. Additional LAG-3 products, including antibodies for immune response modulation, are being developed by Immutep’s large pharmaceutical partners.

Further information can be found on the Company’s website www.immutep.com or by contacting:

Australian Investors/Media:

Catherine Strong, Citadel-MAGNUS
+61 (0)406 759 268; [email protected]

U.S. Media:

Tim McCarthy, LifeSci Advisors
+1 (212) 915.2564; [email protected]



Fusion Pharmaceuticals Appoints Eric S. Hoffman, Ph.D. as Senior Vice President, Business Development

PR Newswire

HAMILTON, ON and BOSTON, Sept. 21, 2021 /PRNewswire/ — Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the appointment of Eric S. Hoffman, Ph.D. as senior vice president, business development.

“The field of radiopharmaceuticals is experiencing a resurgence of interest and excitement, and Fusion is well-positioned with a platform to create differentiated targeted alpha therapies (TATs) from a wide range of targeting molecules, including antibodies and small molecules,” said Fusion Chief Executive Officer John Valliant, Ph.D. “With the expansion of our pipeline of TATs through both proprietary and partnered programs, expanding our leadership team is a key part of our strategy to meet the growth opportunities in front of us. To that end, Eric brings to our team deep business development and corporate strategy experience, combined with a scientific and finance background.”

Dr. Hoffman has more than 15 years’ experience in the biotechnology industry, most recently acting as chief business officer at Vicarius Pharma, where he led successful business development efforts to in-license European commercialization rights for oncology and other products. Prior to Vicarius, he was chief business officer of Genocea Biosciences where he led business development, alliance management and commercial operations. Prior to Genocea, he was vice president of corporate and business development and executive director of investor relations and corporate communications at Idenix Pharmaceuticals until the acquisition by Merck & Co. Dr. Hoffman was previously director of corporate and business development and director of investor relations at Biogen Idec. He also previously worked for more than five years on Wall Street as a biotechnology equity analyst at JPMorgan Securities and a biotechnology research associate at Bear Stearns International.

Dr. Hoffman was a post-doctoral research associate in the Department of Immunobiology at King’s College in London. He holds a Ph.D. in molecular, cellular and developmental biology with a focus on T cell immunology from Yale University, and a B.S. in biology from Trinity University.

Inducement Equity Awards

Fusion’s Compensation Committee of the Board of Directors approved a grant of stock options to Dr. Hoffman to purchase 151,000 of Fusion’s common shares. Each option was granted as an inducement equity award outside Fusion’s 2020 Stock Option and Incentive Plan and was made as an inducement material to Dr. Hoffman’s acceptance of employment with Fusion. The options have an exercise price of $8.56 per share, which is equal to the closing price of Fusion’s common stock on September 20, 2021. Each option has a ten-year term and vests over four years, with 25% of the original number of shares vesting on the one-year anniversary of the grant date and then in equal installments for 36 months thereafter, subject to Dr. Hoffman’s continued service with Fusion through the applicable vesting dates.

About Fusion
Fusion Pharmaceuticals is a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines. Employing a proprietary Fast-Clear™ linker technology, Fusion connects alpha particle emitting isotopes to various targeting molecules in order to selectively deliver the alpha emitting payloads to tumors. Fusion’s lead program, FPI-1434 targeting insulin-like growth factor 1 receptor, is currently in a Phase 1 clinical trial. The pipeline includes FPI-1966, targeting the fibroblast growth factor receptor 3 (FGFR3), advancing to a Phase 1 study following the recent investigational new drug (IND) clearance; and FPI-2059, a small molecule targeting neurotensin receptor 1 (NTSR1). In addition to a robust proprietary pipeline, Fusion has a collaboration with AstraZeneca to jointly develop novel targeted alpha therapies (TATs) and combination programs between Fusion’s TATs and AstraZeneca’s DNA Damage Repair Inhibitors (DDRis) and immuno-oncology agents. Fusion has also entered into a collaboration with Merck to evaluate FPI-1434 in combination with Merck’s KEYTRUDA® (pembrolizumab) in patients with solid tumors expressing IGF-1R. Fusion and Hamilton, Ontario-based McMaster University are building a current Good Manufacturing Practice (GMP) compliant radiopharmaceutical manufacturing facility designed to support manufacturing of the Company’s growing pipeline of TATs.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/fusion-pharmaceuticals-appoints-eric-s-hoffman-phd-as-senior-vice-president-business-development-301381345.html

SOURCE Fusion Pharmaceuticals Inc.

Evaxion Biotech Appoints Dr. Birgitte Rønø as Chief Scientific Officer

  • Dr. Rønø has developed Evaxion’s pre-clinical and early clinical oncology pipeline
  • Newly-created Chief Scientific Officer role strengthens Evaxion’s leadership team

COPENHAGEN, Denmark, Sept. 21, 2021 (GLOBE NEWSWIRE) — Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives of patients with cancer, bacterial diseases and viral infections, announced today it has promoted its Senior Director, Immuno-Oncology, Birgitte Rønø, Ph.D, to the newly-created position of Chief Scientific Officer, effective immediately.

Lars Wegner, CEO of Evaxion, said: “As Senior Director of Evaxion’s Cancer Immunotherapy, Birgitte Rønø played a critical role in the development of Evaxion’s pre-clinical and early clinical oncology pipeline. Her appointment as CSO is a well-deserved recognition of her achievements, and she will now take on additional responsibilities to further expand the scientific foundations of Evaxion to advance the development of our pipeline. The CSO position is a new one within Evaxion’s leadership team and comes at a key time for the Company, as we continue to make encouraging progress in the clinic, with two of our lead product candidates expected to advance into Phase 2b trials, one in late 2021 and the other in the first half of 2022.”

Dr. Rønø has more than 15 years’ experience in biopharmaceutical drug discovery, both in academia and industry. Prior to joining Evaxion, Dr. Rønø served as a specialist, team leader and project manager at Novo Nordisk A/S, where she led early drug discovery projects, evaluated in-licensing opportunities, and supported drug development projects with pre-clinical and biomarker expertise.

Birgitte Rønø, CSO of Evaxion, said: “I am very excited to take up my new role as CSO at Evaxion. Having already worked at the company for more than four years, I am intimately familiar with Evaxion’s AI-driven immunotherapies and I am looking forward to taking on a leadership role, as we continue to develop these innovative drug discovery processes to improve the lives of patients.”

Dr. Rønø holds a Bachelor’s Degree in Medicine and a Master’s Degree in Human Biology, both from the University of Copenhagen, Denmark. She received her Ph.D in Experimental Oncology and Immunology from the National Institutes of Health, Bethesda, USA and Copenhagen University Hospital, Denmark.

About Evaxion

Evaxion Biotech A/S is a clinical-stage AI-immunology™ platform company decoding the human immune system to discover and develop novel immunotherapies to treat cancer, bacterial diseases and viral infections. Based on its proprietary and scalable AI-immunology core technology, Evaxion is developing a broad pipeline of novel product candidates which currently includes three patient-specific cancer immunotherapies, two of which are in Phase 1/2a clinical development, both of which are expected to advance into Phase 2b trials, one in late 2021 and the other in the first half of 2022. In addition, Evaxion is advancing a portfolio of vaccines to prevent bacterial and viral infections currently in preclinical development.

For more information  
Evaxion LifeSci Advisors LLC
Glenn S. Vraniak Corey Davis, Ph.D.
Chief Financial Officer Managing Director

[email protected]

[email protected]
+1 (513) 476-2669 212-915-2577

Source: Evaxion Biotech

Forward-looking statement

This announcement contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this announcement regarding the Company’s future operations, plans and objectives are forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, all statements other than statements of historical fact included in this announcement about future events are subject to (i) change without notice and (ii) factors beyond the Company’s control. These statements may include, without limitation, any statements preceded by, followed by, or including words such as “target,” “believe,” “expect,” “hope,” “aim,” “intend,” “may,” “might,” “anticipate,” “contemplate,” “continue,” “estimate,” “plan,” “potential,” “predict,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could,” and other words and terms of similar meaning or the negative thereof. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including but not limited to: risks associated with the Company’s financial condition and need for additional capital; risks associated with the Company’s development work; cost and success of the Company’s product development activities and preclinical and clinical trials; risks related to commercializing any approved pharmaceutical product developed using the Company’s AI platform technology, including the rate and degree of market acceptance of the Company’s product candidates; risks related to the Company’s dependence on third parties including for conduct of clinical testing and product manufacture; risks associated with the Company’s inability to enter into partnerships; risks related to government regulation; risks associated with protection of the Company’s intellectual property rights; risks related to employee matters and managing growth; risks related to the Company’s ADSs and ordinary shares, risks associated with the pandemic caused by the coronavirus known as COVID-19 and other risks and uncertainties affecting the Company’s business operations and financial condition.

Forward-looking statements are subject to inherent risks and uncertainties beyond the Company’s control that could cause the Company’s actual results, performance, or achievements to be materially different from the expected results, performance, or achievements expressed or implied by such forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the Company’s business in general, see the risks described in the “Risk Factors” section included in the Company’s Form 20-F for the year ended December 31, 2020 and the Company’s other reports filed with, or submitted to, the U.S. Securities and Exchange Commission (SEC). Any forward-looking statements contained in this announcement speak only as of the date hereof, and except as required by law, the Company assumes no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.



GreenBox POS Selects Miami as Headquarters for its Stablecoin Spin-off, Coyni

SAN DIEGO, CA, Sept. 21, 2021 (GLOBE NEWSWIRE) — GreenBox POS (NASDAQ: GBOX) (“GreenBox” or the “Company”), an emerging financial technology company leveraging proprietary blockchain security to build customized payment solutions, announced it has selected Miami as its headquarters for its stablecoin spinoff company, Coyni.

Miami is quickly becoming a hub for Fintech companies driven by the strong advocacy and leadership from Mayor Francis Suarez. The city hosted this year’s Bitcoin conference and is moving towards the acceptance of tax payments in Bitcoin enabling city workers to be eligible to receive part of their pay in Bitcoin. Several top financial firms and investors have recently launched startups or moved to the city including former CEO of Paypal, Bill Harris, who chose Miami for his digital bank start up, Nirvana. GreenBox is currently in the process of evaluating office space and appointing the Coyni executive management team in preparation for its upcoming spin-off and initial public offering.

“Miami’s growth in attracting leading Fintech companies as well as its embrace of digital and crypto currency makes it a natural fit as Coyni’s primary base of operations,” said Fredi Nisan, Chief Executive Officer of GreenBox POS. “Being at the center of a multicultural region that is supportive of digital currency trends with branches to South America and the Caribbean position Coyni well for rapid adoption and expansion. We look forward to being a part of Miami’s fintech community and bringing our innovative financial technology to markets everywhere.”

About GreenBox POS

GreenBox POS (NASDAQ: GBOX) is an emerging financial technology company leveraging proprietary blockchain security to build customized payment solutions. The Company’s applications enable an end-to-end suite of turnkey financial products, fraud detection and improving the efficiency of handling large-scale commercial processing volumes for its merchant clients. For more information, please visit the Company’s website at www.greenboxpos.com.

Forward-Looking Statements Disclaimer

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the Company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set out in the Company’s SEC filings. These risks and uncertainties could cause the Company’s actual results to differ materially from those indicated in the forward-looking statements.

Investor Relations Contact

Mark Schwalenberg
MZ Group – MZ North America
312-261-6430
[email protected]
www.mzgroup.us



Gossamer Bio Announces Appointment of Bryan Giraudo as Chief Operating Officer, in addition to Chief Financial Officer Role

Gossamer Bio Announces Appointment of Bryan Giraudo as Chief Operating Officer, in addition to Chief Financial Officer Role

SAN DIEGO–(BUSINESS WIRE)–Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that, Bryan Giraudo has been appointed Chief Operating Officer, in addition to his continued role as Chief Financial Officer. Mr. Giraudo joined Gossamer in May 2018 as its Chief Financial Officer.

“Bryan has been instrumental in strengthening the financial and organizational foundation of the Company,” said Faheem Hasnain, Chairman, co-founder and CEO of Gossamer Bio. “Since his arrival at Gossamer, his responsibilities have extended far beyond just the finance and accounting groups, and this promotion reflects the management and leadership role that Bryan has already established for himself.”

Prior to joining Gossamer Bio, Mr. Giraudo was a Senior Managing Director at Leerink Partners, now known as SVB Leerink, from 2009 to April 2018. Before joining Leerink, Mr. Giraudo was a Managing Director in Merrill Lynch’s Global Healthcare Investment Banking Group.

About Gossamer Bio

Gossamer Bio is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology. Its goal is to be an industry leader in each of these therapeutic areas and to enhance and extend the lives of patients suffering from such diseases.

For Investors and Media:

Bryan Giraudo, Chief Operating Officer & Chief Financial Officer

Gossamer Bio Investor Relations

[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: General Health Health Science Pharmaceutical Research

MEDIA:

Logo
Logo

Thinking about buying stock in Rewalk Robotics, Viridian Therapeutics, CohBar, Golden Ocean Group, or Indie Semiconductor?

PR Newswire

NEW YORK, Sept. 21, 2021 /PRNewswire/ — InvestorsObserver issues critical PriceWatch Alerts for RWLK, VRDN, CWBR, GOGL, and INDI.

To see how InvestorsObserver’s proprietary scoring system rates these stocks, view the InvestorsObserver’s PriceWatch Alert by selecting the corresponding link.

(Note: You may have to copy this link into your browser then press the [ENTER] key.)

InvestorsObserver’s PriceWatch Alerts are based on our proprietary scoring methodology. Each stock is evaluated based on short-term technical, long-term technical and fundamental factors. Each of those scores is then combined into an overall score that determines a stock’s overall suitability for investment.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/thinking-about-buying-stock-in-rewalk-robotics-viridian-therapeutics-cohbar-golden-ocean-group-or-indie-semiconductor-301381427.html

SOURCE InvestorsObserver

Rush Street Interactive Names Tammi Barlow Director of Corporate Social Responsibility

Announcement Coincides with the American Gaming Association’s Responsible Gaming Education Week

PR Newswire

CHICAGO, Sept. 21, 2021 /PRNewswire/ — Rush Street Interactive, Inc. (NYSE: RSI) (“RSI” or the “Company”), a leading online casino and sports betting company in the United States, today announced the appointment of Tammi Barlow as Director of Corporate Social Responsibility. Ms. Barlow brings over a decade of experience building and managing responsible gaming and corporate social responsibility programs for companies in the gaming industry.

In this new role, Ms. Barlow will lead the development and execution of RSI’s corporate social responsibility strategy, including the continued implementation of the Company’s responsible gaming initiatives as well as promotion and expansion of the Company’s diversity, equity, and inclusion and environmental, social, and governance efforts with internal and external stakeholders. Ms. Barlow reports to RSI’s Chief Compliance Officer, Laura McAllister Cox, a seasoned legal advisor to the gaming industry and regulatory and compliance professional who formally joined the Company earlier this year. Ms. Cox previously supported RSI’s compliance efforts for over five years in her role as Vice President of Regulatory Compliance and Legal Counsel at Rush Street Gaming, LLC.

“As legal online gaming continues to expand across the country, it is critical that our industry’s customers and employees are equipped with the tools and resources necessary to help ensure safe and fun gambling experiences,” said Richard Schwartz, Chief Executive Officer of RSI. “Tammi is a highly experienced executive with a demonstrated history of developing successful responsible gaming programs. RSI remains focused on being at the forefront of this important topic and we are proud to further our commitment to serving as a good corporate citizen with Tammi’s addition to the team.”

Since inception, RSI has prioritized the deployment of best-in-class responsible gaming tools within its products. Recent innovations include faster, transparent, and non-cancellable withdraw and refund processes; regular reviews of customer match criteria to prevent breaches in jurisdictional self-exclusion databases; and the continued integration of prominent responsible gaming messaging in customer-facing communications.  

“I have long admired RSI for its thought leadership and continuous improvement approach to responsible gaming efforts,” said Ms. Barlow. “Together with our partners in the industry, I look forward to educating RSI’s stakeholders on the risks and rewards associated with gambling and empowering them to make smart decisions that create a betting gaming industry and better society.”

Prior to joining RSI, Ms. Barlow served as Director of Responsible Gaming and Corporate Social Responsibility at Caesars Entertainment, Inc. following its acquisition of William Hill PLC. Before that, she was the Head of Responsible Gaming at William Hill PLC and Director of Responsible Gaming and Corporate Social Responsibility at William Hill US. Previously, she served as Manager of Responsible Gaming & Community Relations at International Game Technology (IGT). Ms. Barlow’s career in the gaming industry began as the Manager of Corporate Social Responsibility at Northstar Lottery Group, LLC. She currently serves as a subject matter expert on Nevada Governor Steve Sisolak’s Advisory Committee on Problem Gambling. 

RSI is partnering with and supporting the American Gaming Association’s 2021 observance of Responsible Gaming Education Week taking place September 19-24. The week provides an opportunity for gaming operators to refresh employee training, promote transparency and gaming literacy to customers, and work with community partners on advancing responsible gaming initiatives through events and educational resources.

About RSI
RSI is a trusted online gaming and sports entertainment company focused on regulated markets in the United States and Latin America. Through its brands, BetRivers.com and PlaySugarHouse.com, RSI was an early entrant in many regulated jurisdictions and is currently live with real-money mobile, online and/or retail operations in ten U.S. states: Pennsylvania, Illinois, New Jersey, New York, Michigan, Indiana, Virginia, Colorado, Iowa and West Virginia. RSI is also active internationally, offering its online casino and sportsbook in the regulated gaming market of Colombia on RushBet.co. RSI offers, through its proprietary online gaming platform, some of the most popular online casino games and sports betting options in the United States. Founded in 2012 in Chicago by gaming industry veterans, RSI was named the 2020 Global Gaming Awards Digital Operator of the Year and the 2021 EGR North America Awards Casino Operator of the Year, Customer Services Operator of the Year and Social Gaming Operator of the Year. RSI is committed to industry-leading responsible gaming practices and seeks to provide its customers with the resources and services they need to play responsibly. For more information, visit www.rushstreetinteractive.com.

Investors:
[email protected]

Cision View original content:https://www.prnewswire.com/news-releases/rush-street-interactive-names-tammi-barlow-director-of-corporate-social-responsibility-301381331.html

SOURCE Rush Street Interactive

Blue Ridge Bank Announces Partnership with Mos

PR Newswire

RICHMOND, Va., Sept. 21, 2021 /PRNewswire/ — Blue Ridge Bank, N.A., the national bank subsidiary of Blue Ridge Bankshares, Inc. (NYSE American: BRBS), announces its partnership with Mos, a student financial aid fintech company helping students navigate the financial aid application process to reduce student debt and build a healthy financial future.


Mos
 provides students access to every grant and scholarship for which they are eligible, maximizing the funds available to defray the frequently burdensome costs of college. Working with Blue Ridge Bank, Mos added debit card services and a banking app for students to its financial services suite.


Mos
 partnered with Unit, a leader in next generation embedded finance, to build the additional functionality. “Our mission is to help companies offer banking services to their unique audiences, unlock value, and expand financial access for all,” said Itai Damti, Chief Executive Officer of Unit. “Mos has been exceptionally successful at serving the financial needs of students so far. We’re excited to support their expansion into a modern banking experience that speaks its audience’s language and addresses its needs.”

“We are excited about partnering with Mos,” said Brian K. Plum, President and Chief Executive Officer of Blue Ridge Bank. “Our work together reinforces our belief that the evolution of financial service delivery through improved technology enhances the financial lives of users. We have been focused for years on improving financial literacy and outcomes for Americans, and this partnership advances this important work.”

Amira Yahyaoui, Chief Executive Officer and founder of Mos, said “Our mission at Mos is to tear down all financial barriers to opportunity—Blue Ridge Bank enabled us to begin our journey of fulfilling this mission at a faster pace.”

About Blue Ridge Bank:

Blue Ridge Bank, N.A., is the wholly owned banking subsidiary of Blue Ridge Bankshares, Inc. Through its subsidiaries and affiliates, Blue Ridge Bank provides a wide range of financial services including retail and commercial banking, payroll, insurance, card payments, wholesale and retail mortgage lending, and government-guaranteed lending. Visit mybrb.bank to learn more.

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/blue-ridge-bank-announces-partnership-with-mos-301381302.html

SOURCE Blue Ridge Bank, N.A.

Planet Fitness, Home of the Judgement Free Zone, and the Coalition for Inclusive Fitness, Announce Accessible Exercise Equipment Commitment Benefitting People with Disabilities

PR Newswire

HAMPTON, N.H., Sept. 21, 2021 /PRNewswire/ — Planet Fitness, Inc. (NYSE: PLNT), one of the largest and fastest-growing global franchisors and operators of fitness centers with more members than any other fitness brand, and the Paralyzed Veterans of America, National Council on Independent Living, and American Council of the Blind (collectively “Coalition for Inclusive Fitness” or the “Coalition”) today announced a commitment to expand access to accessible exercise equipment.

“As a leader in the industry and home of the Judgement Free Zone®, it is our mission to provide an inclusive and welcoming environment to anyone who comes through our doors,” said Chris Rondeau, Planet Fitness’ Chief Executive Officer. “People with disabilities face significant barriers when attempting to access health and wellness activities, and it’s clear that health inequity is often due to a lack of access and opportunity. Today’s commitment is another way we are working to eliminate barriers and enhance people’s lives by providing a high-quality fitness experience for everyone.”

The Coalition is focused on working with global organizations to build inclusive health communities that provide people with disabilities equal access to, and opportunities for, healthy living.  Planet Fitness is committed to providing inclusive equipment in all new clubs and adding it to existing clubs across the country as franchise owners replace current offerings, as inclusive commercial grade equipment becomes available for purchase and is approved by Planet Fitness for inclusion in its clubs.

Planet Fitness will enhance the amount and variety of accessible equipment provided at its clubs by adding new inclusive equipment that conforms with ASTM standards as it becomes commercially available for purchase after clearing through a due diligence process, in accordance with set phased-in time parameters. 

This equipment will include:

  • An inclusive dual cable strength machine that allows a person to perform multiple exercises from a seated position, including from a wheelchair.
  • A recumbent cardio machine where movement of the arms can move the legs, and vice-versa, and, in addition, the seat can be removed so it can be operated from a wheelchair.
  • Multiple cardio machines, which, depending upon availability, can include: treadmills, elliptical devices, upright bikes and/or recumbent bikes.
  • All new cardio machines will have inclusive features including raised tactile buttons and the ability to receive audible instructions and performance feedback through headphones. This will enable blind users to operate cardio machines independently.

Planet Fitness will also include the inclusive fitness symbol on all accessible equipment, share information about the roll-out of accessible equipment on its website (as it becomes available in its clubs), and continue its practice of providing customer service regarding the use of accessible equipment. 

“We applaud Planet Fitness for this historic commitment to the disability community,” said Richard Thesing, Coalition for Inclusive Fitness’ Chief Executive Officer.  “At the present time, there are no cardio machines that can be used by blind people and very few fitness centers have cardio or strength machines that can be used by people with mobility disabilities. This marks a huge step forward towards providing individuals with disabilities with a truly inclusive fitness experience. We hope this will be the start of an industry-wide effort to provide individuals with disabilities the opportunity to enjoy an accessible fitness experience and take similar steps to making that a reality.”

“People who are blind face a myriad of chronic health conditions due in no small part to the lack of accessible exercise and fitness equipment available in the market today,” said Eric Bridges, Executive Director, American Council of the Blind. “The lack of accessible user interfaces and audible output for nearly all types of exercise and fitness equipment prevents people who are blind and experiencing vision loss from independently operating, purchasing and enjoying the use of fitness and exercise equipment, and thereby taking control of their own health and wellbeing.  ACB applauds Planet Fitness for their collaboration with the disability community, and we encourage other fitness and exercise providers to follow their leadership to enable people with disabilities the freedom to take control of their health.”

“Exercise is for everyone,” said Emily Seelenfreund, Staff Attorney at Disability Rights Advocates – one of the organizations representing the Coalition.  “Planet Fitness’ pioneering commitment to increasing accessibility should serve as a model for fitness facilities across the country.”

“For people with spinal cord injuries and disorders, being able to access exercise equipment that meets their needs can be essential to maintaining an exercise program that increases their strength and endurance for rehabilitation, health, and overall sense of well-being,” said Heather Ansley, Associate Executive Director of Government Relations, Paralyzed Veterans of America.  “We believe that this commitment will help make accessible equipment more available in people’s communities and we are pleased that Planet Fitness has stepped forward to help meet this critical need.”

About Planet Fitness
Founded in 1992 in Dover, NH, Planet Fitness is one of the largest and fastest-growing franchisors and operators of fitness centers in the United States by number of members and locations. As of June 30, 2021, Planet Fitness had more than 14.8 million members and 2,170 stores in 50 states, the District of Columbia, Puerto Rico, Canada, Panama, Mexico and Australia. The Company’s mission is to enhance people’s lives by providing a high-quality fitness experience in a welcoming, non-intimidating environment, which we call the Judgement Free Zone®. More than 95% of Planet Fitness stores are owned and operated by independent business men and women.

About Paralyzed Veterans of America
The Paralyzed Veterans of America (pva.org), is a congressionally chartered veterans’ service organization and is the largest organization for veterans with a spinal cord injury, multiple sclerosis, amyotrophic lateral sclerosis and other diseases and conditions resulting in paralysis.

About
The National Council on Independent Living
The National Council on Independent Living (ncil.org), is a national cross disability, grassroots organization run by and for people with disabilities representing thousands of organizations and individuals, including individuals with disabilities, Centers for Independent Living, statewide Independent Living Councils and other organizations that advocate for human and civil rights of people with disabilities throughout the United States.

About
The American Council on the Blind
The American Council on the Blind (acb.org), is comprised of approximately 70 state chapters and special interest affiliates representing a diverse range of groups within the blind community.

About Mobility Fitness
Mobility Fitness’ mission is to ensure that every entity, worldwide, that offers exercise equipment to its patrons will also offer inclusive equipment. mobilityfitness.org

About Disability Rights Advocates:
With offices in New York and California, Disability Rights Advocates is the leading nonprofit disability rights legal center in the nation. Its mission is to advance equal rights and opportunity for people with all types of disabilities nationwide. DRA represents people with all types of disabilities in complex, system-changing, class action cases. DRA is proud to have upheld the promise of the ADA since our inception. Thanks to DRA’s precedent-setting work, people with disabilities across the country have dramatically improved access to education, health care, employment, transportation, disaster preparedness planning, voting, and housing. For more information, visit dralegal.org

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/planet-fitness-home-of-the-judgement-free-zone-and-the-coalition-for-inclusive-fitness-announce-accessible-exercise-equipment-commitment-benefitting-people-with-disabilities-301381295.html

SOURCE Planet Fitness, Inc.

Sanmina Strengthens Focus on Extensive Optical, RF and Microelectronics Capabilities

Brands Optical, RF and Microelectronics Division as Advanced Micro Systems Technologies; Leverages 15 Years of Experience to Capitalize on Growing Demand for Highly-Integrated Technology Products

PR Newswire

SAN JOSE, Calif., Sept. 21, 2021 /PRNewswire/ — Sanmina Corporation (NASDAQ: SANM), a leading integrated manufacturing solutions company that manufactures some of the world’s most complex and innovative electronic and optical products, today announced that it is strengthening its focus on its extensive optical, radio frequency (RF) and microelectronics (microE) design and manufacturing capabilities to capitalize on growing demand for highly-integrated technology products. The division has been formalized under a new brand called Advanced Micro Systems Technologies (AMST) and leverages more than 15 years of experience providing mixed technology design and assembly services and best-in-class manufacturing solutions. AMST offers end-to-end solutions to high growth, high value markets, including the communications, 5G, computing, datacenter, medical, automotive and industrial sectors, as demand for highly-integrated technology products continues to grow.

Increased speed and performance requirements are driving technology needs for integration that pack highly complex, high speed, mixed technology solutions into dramatically smaller form factors. AMST utilizes Sanmina’s strong history of vertical integration expertise and provides end-to-end services to Original Equipment Manufacturers and component suppliers including design, simulation, process and test development, prototyping, design validation, product qualification and manufacturing across its global footprint.

“We’re very excited to strengthen our focus under the new AMST name,” said Eric Sislian, VP of the AMST division at Sanmina. “Integrating our leading optical, RF and microE capabilities into a cohesive ecosystem and leveraging our strengths in design, engineering and advanced global manufacturing into a comprehensive end-to-end service offering enables us to develop compelling technology roadmaps that help our customers win in their respective markets.”

Sanmina has a strong history of developing mixed technology products, integrating RF and optical technologies that utilize its microelectronic design and assembly capabilities. Extensive packaging expertise enables solutions in customer and industry defined footprints – from microelectronic packages, to small form factor subsystems and board level solutions.

“AMST is well positioned to support growing industry demand for silicon photonics, 5G mmWave and multi-chip packaging solutions that integrate optical, RF and mixed-signal technologies in high-density form factors,” said Mike Landy, President and COO of IMS Worldwide at Sanmina. “It represents the culmination of more than 15 years of experience developing product and process solutions and we will continue making strategic investments in this area to support customer growth.”

The AMST division has product development and high-volume manufacturing capabilities across the United States, Canada, Mexico, China and Thailand.

About Sanmina

Sanmina Corporation, a Fortune 500 company is a leading integrated manufacturing solutions provider serving the fastest growing segments of the global Electronics Manufacturing Services (EMS) market. Recognized as a technology leader, Sanmina provides end-to-end manufacturing solutions, delivering superior quality and support to Original Equipment Manufacturers (OEMs) primarily in the communications networks, cloud solutions, industrial, defense, medical and automotive. Sanmina has facilities strategically located in key regions throughout the world. More information about the Company is available at www.sanmina.com.

Sanmina Safe Harbor Statement

The foregoing, including the discussion regarding the Company’s future prospects, contains certain forward-looking statements that involve risks and uncertainties, including uncertainties associated with economic conditions in the electronics industry, particularly in the principal industry sectors served by the Company, changes in customer requirements and in the volume of sales principal customers, the ability of Sanmina to effectively assimilate acquired businesses and achieve the anticipated benefits of its acquisitions, and competition and technological change. The Company’s actual results of operations may differ significantly from those contemplated by such forward-looking statements as a result of these and other factors, including factors set forth in our Company’s Annual and quarterly reports filed with the Securities Exchange Commission.

Logo: https://mma.prnewswire.com/media/10544/SANMINA_CORPORATION_LOGO.jpg

Cision View original content:https://www.prnewswire.com/news-releases/sanmina-strengthens-focus-on-extensive-optical-rf-and-microelectronics-capabilities-301381321.html

SOURCE Sanmina Corporation